Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring

Molecular and Cellular Proteomics

Volumn 12, Issue 10, 2013, Pages 2761-2773

  Végvári, Ákos ^a   Sjödin, Karin ^a   Rezeli, Melinda ^a   Malm, Johan ^b   Lilja, Hans ^b,c,d,e   Laurell, Thomas ^a,f   Marko Varga, Gyorgy ^a,g  

^a LUND UNIVERSITY   (Sweden)

^b Malmö University Hospital   (Sweden)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f Dongguk University   (South Korea)

^g TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN 6; KALLIKREIN RELATED PEPTIDASE 2; PEPTIDASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MALE INFERTILITY; MONITORING; MULTIPLE REACTION MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEOMICS; QUANTITATIVE ANALYSIS; SEMEN ANALYSIS; SEMINAL PLASMA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SPERM; TANDEM MASS SPECTROMETRY;

BIOLOGICAL ASSAY; HUMANS; MALE; OLIGOPEPTIDES; PLASMA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; SEMEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84885092136     PISSN: 15359476     EISSN: 15359484     Source Type: Journal    
DOI: 10.1074/mcp.M113.028365     Document Type: Article

References (49)

1. Rifai, N., Gillette, M. A., and Carr, S. A. (2006) Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat. Biotechnol. 24, 971-983
2. Makawita, S., and Diamandis, E. P. (2010) The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin. Chem. 56, 212-222
3. Domanski, D., Percy, A. J., Yang, J., Chambers, A. G., Hill, J. S., Freue, G. V. C., and Borchers, C. H. (2012) MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 12, 1222-1243
4. Barr, J. R., Maggio, V. L., Patterson, D. G., Cooper, G. R., Henderson, L. O., Turner, W. E., Smith, S. J., Hannon, W. H., Needham, L. L., and Sampson, E. J. (1996) Isotope dilution mass spectrometric quantification of specific proteins: model application with apolipoprotein A-I. Clin. Chem. 42, 1676-1682
5. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J., Jackson, A. M., Hardie, D. B., Anderson, N. L., and Borchers, C. H. (2009) Multiple reaction monitoringbased, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell. Proteomics 8, 1860-1877
6. Berna, M., and Ackermann, B. (2009) Increased throughput for low-abundance protein biomarker verification by liquid chromatography/tandem mass spectrometry. Anal. Chem. 81, 3950-3956
7. Paulovich, A. G., Whiteaker, J. R., Hoofnagle, A. N., and Wang, P. (2008) The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin. Appl. 2, 1386-1402
8. Barnidge, D. R., Goodmanson, M. K., Klee, G. G., and Muddiman, D. C. (2004) Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-MS/MS using protein cleavage and isotope dilution mass spectrometry. J. Proteome Res. 3, 644-652
9. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., and Carr, S. A. (2007) Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 6, 2212-2229
10. Kulasingam, V., Smith, C. R., Batruch, I., Buckler, A., Jeffery, D. A., and Diamandis, E. P. (2008) "Product ion monitoring" assay for prostatespecific antigen in serum using a linear ion-trap. J. Proteome Res. 7, 640-647
11. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., Hall, S. C., Allen, S., Blackman, R. K., Borchers, C. H., Buck, C., Cardasis, H. L., Cusack, M. P., Dodder, N. G., Gibson, B. W., Held, J. M., Hiltke, T., Jackson, A., Johansen, E. B., Kinsinger, C. R., Li, J., Mesri, M., Neubert, T. A., Niles, R. K., Pulsipher, T. C., Ransohoff, D., Rodriguez, H., Rudnick, P. A., Smith, D., Tabb, D. L., Tegeler, T. J., Variyath, A. M., Vega-Montoto, L. J., Wahlander, A., Waldemarson, S., Wang, M., Whiteaker, J. R., Zhao, L., Anderson, N. L., Fisher, S. J., Liebler, D. C., Paulovich, A. G., Regnier, F. E., Tempst, P., and Carr, S. A. (2009) Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 27, 633-641
12. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C., Bettsworth, F., Lacoux, X., Choquet-Kastylevsky, G., and Lemoine, J. (2009) Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem. 81, 9343-9352
13. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C., Lacoux, X., Morla, A., Choquet-Kastylevsky, G., and Lemoine, J. (2009) Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 8, 1006-1015
14. Selevsek, N., Matondo, M., Carbayo, M. S., Aebersold, R., and Domon, B. (2011) Systematic quantification of peptides/proteins in urine using selected reaction monitoring. Proteomics 11, 1135-1147
15. Liu, T., Hossain, M., Schepmoes, A. A., Fillmore, T. L., Sokoll, L. J., Kronewitter, S. R., Izmirlian, G., Shi, T., Qian, W.-J., Leach, R. J., Thompson, I. M., Chan, D. W., Smith, R. D., Kagan, J., Srivastava, S., Rodland, K. D., and Camp Ii, D. G. (2012) Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests. J. Proteomics 75, 4747-4757
16. Shi, T., Fillmore, T. L., Sun, X., Zhao, R., Schepmoes, A. A., Hossain, M., Xie, F., Wu, S., Kim, J.-S., Jones, N., Moore, R. J., Paša- Tolić, L., Kagan, J., Rodland, K. D., Liu, T., Tang, K., Camp, D. G., Smith, R. D., and Qian, W.-J. (2012) Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. U. S. A. published ahead of print September 4, 2012, doi:10.1073/pnas.1204366109
17. Enjalbert, Q., Girod, M., Simon, R., Jeudy, J., Chirot, F., Salvador, A., Antoine, R., Dugourd, P., and Lemoine, J. (2013) Improved detection specificity for plasma proteins by targeting cysteine-containing peptides with photo-SRM. Anal. Bioanal. Chem. 405, 2321-2331
18. Li, Y., Tian, Y. A., Rezai, T., Prakash, A., Lopez, M. F., Chan, D. W., and Zhang, H. (2011) Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. Anal. Chem. 83, 240-245
19. Prakash, A., Rezai, T., Krastins, B., Sarracino, D., Athanas, M., Russo, P., Zhang, H., Tian, Y., Li, Y., Kulasingam, V., Drabovich, A., Smith, C. R., Batruch, I., Oran, P. E., Fredolini, C., Luchini, A., Liotta, L., Petricoin, E., Diamandis, E. P., Chan, D. W., Nelson, R., and Lopez, M. F. (2012) Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J. Proteome Res. 11, 3986-3995
20. Rafalko, A., Dai, S., Hancock, W. S., Karger, B. L., and Hincapie, M. (2012) Development of a Chip/Chip/SRM platform using digital chip isoelectric focusing and LC-Chip mass spectrometry for enrichment and quantitation of low abundance protein biomarkers in human plasma. J. Proteome Res. 11, 808-817
21. Yocum, A. K., Khan, A. P., Zhao, R., and Chinnaiyan, A. M. (2010) Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer. Proteomics 10, 3506-3514
22. Lilja, H. (1985) A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J. Clin. Invest. 76, 1899-1903
23. Lilja, H., Oldbring, J., Rannevik, G., and Laurell, C. B. (1987) Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J. Clin. Invest. 80, 281-285
24. Lilja, H., Abrahamsson, P. A., and Lundwall, A. (1989) Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J. Biol. Chem. 264, 1894-1900
25. Lundwall, A., and Lilja, H. (1987) Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 214, 317-322
26. Christensson, A., Laurell, C. B., and Lilja, H. (1990) Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 194, 755-763
27. Balk, S. P., Ko, Y. J., and Bubley, G. J. (2003) Biology of prostate-specific antigen. J. Clin. Oncol. 21, 383-391
28. Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., and Lövgren, T. (1991) Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37, 1618-1625
29. Stenman, U. H., Leinonen, J., Alfthan, H., Rannikko, S., Tuhkanen, K., and Alfthan, O. (1991) A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51, 222-226
30. Vickers, A. J., Cronin, A. M., Björk, T., Manjer, J., Nilsson, P. M., Dahlin, A., Bjartell, A., Scardino, P. T., Ulmert, D., and Lilja, H. (2010) Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ 341, c4521
31. Lilja, H., Cronin, A. M., Dahlin, A., Manjer, J., Nilsson, P. M., Eastham, J. A., Bjartell, A. S., Scardino, P. T., Ulmert, D., and Vickers, A. J. (2011) Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117, 1210-1219
32. Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., Denis, L. J., Recker, F., Páez, A., Määttänen, L., Bangma, C. H., Aus, G., Carlsson, S., Villers, A., Rebillard, X., van der Kwast, T., Kujala, P. M., Blijenberg, B. G., Stenman, U.-H., Huber, A., Taari, K., Hakama, M., Moss, S. M., de Koning, H. J., and Auvinen, A. (2012) Prostate-cancer mortality at 11 years of follow-up. N. Engl. J. Med. 366, 981-990
33. Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., and Lilja, H. (2010) Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725-732
34. Moyer, V. A. (2012) Screening for prostate cancer: U. S. Preventive Services Task Force recommendation statement. Ann. Intern. Med. 157, 120-134
35. Vickers, A. J., Roobol, M. J., and Lilja, H. (2012) Screening for prostate cancer: early detection or overdetection? Annu. Rev. Med. 2012, 161-170
36. Lilja, H., Ulmert, D., and Vickers, A. J. (2008) Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8, 268-278
37. Kelleher, N. (2012) A cell-based approach to the Human Proteome Project. J. Am. Soc. Mass Spectrom. 23, 1617-1624
38. Végvári, Á., Rezeli, M., Sihlbom, C., Häkkinen, J., Carlsohn, E., Malm, J., Lilja, H., Laurell, T., and Marko-Varga, G. (2012) Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. Clin. Biochem. 45, 331-338
39. Mitrunen, K., Pettersson, K., Piironen, T., Björk, T., Lilja, H., and Lövgren, T. (1995) Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin. Chem. 41, 1115-1120
40. Klein, R. J., Halldén, C., Cronin, A. M., Ploner, A., Wiklund, F., Bjartell, A. S., Stattin, P., Xu, J., Scardino, P. T., Offit, K., Vickers, A. J., Grönberg, H., and Lilja, H. (2010) Blood biomarker levels to aid discovery of cancerrelated single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev. Res. 3, 611-619
41. Rodriguez, S., Al-Ghamdi, O. A., Burrows, K., Guthrie, P. A. I., Lane, J. A., Davis, M., Marsden, G., Alharbi, K. K., Cox, A., Hamdy, F. C., Neal, D. E., Donovan, J. L., and Day, I. N. M. (2013) Very low PSA concentrations and deletions of the KLK3 gene. Clin. Chem. 59, 234-244
42. Emami, N., and Diamandis, E. P. (2007) New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family. Mol. Oncol. 1, 269-287
43. Lim, A., Prokaeva, T., McComb, M. E., O'Connor, P. B., Théberge, R., Connors, L. H., Skinner, M., and Costello, C. E. (2002) Characterization of transthyretin variants in familial transthyretin amyloidosis by mass spectrometric peptide mapping and DNA sequence analysis. Anal. Chem. 74, 741-751
44. Nepomuceno, A. I., Mason, C. J., Muddiman, D. C., Bergen, H. R., and Zeldenrust, S. R. (2004) Detection of genetic variants of transthyretin by liquid chromatography-dual electrospray ionization Fourier-transform ion-cyclotron-resonance mass spectrometry. Clin. Chem. 50, 1535-1543
45. Connors, L. H., Yamashita, T., Yazaki, M., Skinner, M., and Benson, M. D. (2004) A rare transthyretin mutation (Asp18Glu) associated with cardiomyopathy. Amyloid 11, 61-66
46. Bunger, M. K., Cargile, B. J., Sevinsky, J. R., Deyanova, E., Yates, N. A., Hendrickson, R. C., and Stephenson, J. L. (2007) Detection and validation of non-synonymous coding SNPs from orthogonal analysis of shotgun proteomics data. J. Proteome Res. 6, 2331-2340
47. Rosenzweig, M., Skinner, M., Prokaeva, T., Theberge, R., Costello, C., Drachman, B. M., and Connors, L. H. (2007) A new transthyretin variant (Glu61Gly) associated with cardiomyopathy. J. Proteome Res. 6, 2331-2340
48. Wang, Q., Chaerkady, R., Wu, J., Hwang, H. J., Papadopoulos, N., Kopelovich, L., Maitra, A., Matthaei, H., Eshleman, J. R., Hruban, R. H., Kinzler, K. W., Pandey, A., and Vogelstein, B. (2011) Mutant proteins as cancer-specific biomarkers. Proc. Natl. Acad. Sci. U. S. A. 108, 2444-2449
49. Anderson, N. L., Anderson, N. G., Haines, L. R., Hardie, D. B., Olafson, R. W., and Pearson, T. W. (2004) Mass spectrometric quantitation of peptides and proteins using stable isotope standards and capture by anti-peptide antibodies (SISCAPA). J. Proteome Res. 3, 235-244